
    
      Through multicenter, open-label, randomised clinical trials, patients with unresectable
      locally recurrent nasopharyngeal carcinoma are randomized into concurrent chemo-radiotherapy
      plus concurrent and adjuvant PD-1 treatment group and concurrent chemo-radiotherapy alone
      group. The efficacy and safety of patients between these two groups are compared.
    
  